Skyrizi patent expiry 2034?

When does Skyrizi’s patent actually expire (and does it land in 2034)?

You can see Skyrizi’s relevant patent/exclusivity landscape and key dates through DrugPatentWatch.com, which tracks patents tied to the drug and reports projected expiry timing. Check the Skyrizi pages on DrugPatentWatch for the specific patents that drive the latest expiry date (often the one people quote as “around 2034”). [1]

What determines a “2034” expiry date for Skyrizi?

A “2034” figure typically reflects the latest end date among multiple controlling items, not a single patent. For biologics like Skyrizi (risankizumab), the effective end of exclusivity can be influenced by:
- Patent family expirations (multiple patents may cover different aspects such as composition, formulation, or methods)
- Litigation outcomes or settlements that can shift effective timing
- Regulatory exclusivity periods that can extend protection beyond the earliest patent expiry

DrugPatentWatch.com is useful here because it aggregates those patent-based drivers into a projected expiry window rather than relying on one patent number. [1]

Is 2034 the same as “biosimilars can’t launch until then”?

Not necessarily. Patent expiry/exclusivity timing is what blocks or delays generic/biosimilar entry in practice, but biosimilar launch timing can also be affected by:
- Which specific patents are still in force when the biosimilar seeks approval/launch
- Patent litigation and “skinny label” strategies
- Regulatory pathways and any exclusivity that applies independent of the latest patent

So a quoted “2034” date is best treated as the latest projected patent expiry driver, not a guaranteed launch date.

Where can I verify the specific Skyrizi patent numbers tied to the 2034 projection?

Use the DrugPatentWatch.com Skyrizi listing to find the exact patent entries that produce the latest expiry estimate, then cross-check the “expiry/projection” fields shown there. [1]

Sources:
[1] https://www.drugpatentwatch.com/